HOFSETH BIOCARE ASA financials
HOFSETH BIOCARE ASA
Country: NO Reporting currency: NOK Latest annual report: 2024-12-31
LEI:
5967007LIEEXZXGGEO44 Financial statements
(NOK, as reported — unscaled; 87 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Cost of sales | NOK 169.6M | NOK 150.7M |
| Other income | NOK 592.0K | NOK 4.1M |
| Employee benefits expense | NOK 70.7M | NOK 58.3M |
| Operating profit (EBIT) | -NOK 105.1M | -NOK 102.5M |
| Net finance income / (cost) | -NOK 20.2M | -NOK 4.2M |
| Finance costs | NOK 21.7M | NOK 13.3M |
| Profit before tax | -NOK 125.3M | -NOK 106.7M |
| Income tax expense | NOK 0 | NOK 0 |
| Profit for the year | -NOK 125.3M | -NOK 106.7M |
| Total comprehensive income | -NOK 125.3M | -NOK 106.7M |
| Per share | ||
| Basic EPS | NOK -0.30 | NOK -0.27 |
| Diluted EPS | NOK -0.30 | NOK -0.27 |
| Free cash flow / share | NOK -0.03 | NOK -0.01 |
| Cash flow statement | ||
| Net cash from operating activities | -NOK 9.8M | NOK 2.8M |
| Net cash from investing activities | -NOK 4.1M | -NOK 15.0M |
| Purchase of PP&E (capex) | NOK 2.4M | NOK 8.2M |
| Purchase of intangibles | NOK 1.6M | NOK 5.9M |
| Net cash from financing activities | NOK 15.5M | NOK 3.7M |
| Proceeds from borrowings | NOK 25.1M | NOK 0 |
| Repayments of borrowings | NOK 541.0K | NOK 541.0K |
| Lease liability payments | NOK 12.4M | NOK 13.6M |
| Balance sheet | ||
| Total assets | NOK 339.4M | NOK 390.1M |
| Non-current assets | NOK 227.4M | NOK 259.1M |
| Intangible assets & goodwill | NOK 42.4M | NOK 55.3M |
| Current assets | NOK 112.1M | NOK 131.0M |
| Inventories | NOK 55.9M | NOK 82.5M |
| Trade & other receivables | NOK 18.9M | NOK 14.8M |
| Cash & equivalents | NOK 25.6M | NOK 23.9M |
| Total equity | NOK 59.4M | NOK 41.1M |
| Non-controlling interests | -NOK 689.0K | -NOK 687.0K |
| Non-current liabilities | NOK 111.6M | NOK 97.1M |
| Long-term borrowings | NOK 25.1M | NOK 271.0K |
| Lease liabilities (non-current) | NOK 86.5M | NOK 96.8M |
| Current liabilities | NOK 168.4M | NOK 251.9M |
| Short-term borrowings | NOK 48.0M | NOK 28.9M |
| Lease liabilities (current) | NOK 11.2M | NOK 10.8M |
| Derived metrics | ||
| Free cash flow | -NOK 12.2M | -NOK 5.4M |
| Operating margin | -40.9% | -53.7% |
| Net margin | -48.8% | -55.9% |
| Return on equity | -211.1% | -259.3% |
| Cash conversion ratio | 0.08× | -0.03× |
| Capex coverage | -4.00× | 0.34× |
| Other reported items | ||
| Additional Paidin Capital | NOK 0 | NOK 0 |
| Adjustments For Decrease Increase In Inventories | NOK 26.6M | NOK 34.0M |
| Adjustments For Decrease Increase In Trade Account Receivable | -NOK 4.0M | -NOK 777.0K |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 39.8M | NOK 36.4M |
| Adjustments For Increase Decrease In Trade Account Payable | NOK 38.5M | -NOK 90.6M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -NOK 8.1M | -NOK 23.5M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | -NOK 7.5M | -NOK 2.5M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | NOK 19.4M | NOK 28.4M |
| Cash Repayments of Advances and Loans From Related Parties | NOK 0 | NOK 771.0K |
| Comprehensive Income Attributable To Noncontrolling Interests | -NOK 2.0K | -NOK 1.0K |
| Comprehensive Income Attributable To Owners of Parent | -NOK 125.3M | -NOK 106.7M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 39.8M | NOK 36.4M |
| Equity and Liabilities | NOK 339.4M | NOK 390.1M |
| Finance Income | NOK 9.0M | NOK 6.6M |
| Fixtures and Fittings | NOK 2.5M | NOK 3.3M |
| Gains Losses On Disposals of Noncurrent Assets | NOK 8.1M | NOK 23.6M |
| Income Taxes Paid Refund Classified As Operating Activities | NOK 0 | NOK 0 |
| Increase Decrease In Cash and Cash Equivalents | NOK 1.7M | -NOK 8.5M |
| Increase Decrease Through Sharebased Payment Transactions | — | NOK 0 |
| Increase Decrease Through Transfers and Other Changes Equity | -NOK 193.0K | NOK 9.0K |
| Intangible Assets Other Than Goodwill | NOK 42.4M | NOK 55.3M |
| Interest Paid Classified As Financing Activities | NOK 15.7M | NOK 9.5M |
| Investment Accounted For Using Equity Method | NOK 45.7M | NOK 37.7M |
| Investments In Subsidiaries | NOK 0 | NOK 0 |
| Issue of Equity | NOK 144.0M | — |
| Issued Capital | NOK 4.1M | NOK 4.0M |
| Liabilities | NOK 280.1M | NOK 349.0M |
| Noncurrent Financial Assets | NOK 46.9M | NOK 38.1M |
| Other Adjustments For Noncash Items | NOK 144.0M | NOK 0 |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | NOK 15.7M | NOK 9.5M |
| Other Comprehensive Income | NOK 0 | NOK 0 |
| Other Current Liabilities | NOK 15.6M | NOK 157.0M |
| Other Current Receivables | NOK 11.7M | NOK 9.7M |
| Other Expense By Nature | NOK 90.6M | NOK 75.7M |
| Other Noncurrent Financial Assets | NOK 1.2M | NOK 439.0K |
| Payments For Share Issue Costs | NOK 292.0K | NOK 215.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | NOK 0 | NOK 685.0K |
| Purchase of Interests In Investments Accounted For Using Equity Method | NOK 0 | NOK 1.6M |
| Revenue and Operating Income | NOK 265.5M | NOK 218.5M |
| Revenue From Contracts With Customers | NOK 256.8M | NOK 190.8M |
| Rightofuse Assets That Do Not Meet Definition of Investment Property | NOK 93.7M | NOK 109.6M |
| Share Issue Related Cost | NOK 292.0K | NOK 215.0K |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -NOK 7.5M | NOK 2.5M |
| Share Premium | NOK 55.9M | NOK 37.9M |
| Trade and Other Current Payables To Trade Suppliers | NOK 93.6M | NOK 55.2M |
Methodology
Every line item above is a fact tagged in HOFSETH BIOCARE ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.